phrykt

Xenon Pharmaceuticals Inc. (XENE): who owns it and who trades it

As of Nov 16, 2026, XENE insiders reported 26 open-market sales worth $22M and 2 purchases worth $1.7M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ian Mortimer (CEO), with $20.3M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Xenon Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns XENE

314 funds and institutions reported XENE shares worth $6.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 10.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)10.0%
BlackRock, Inc.7.8%
Avoro Capital Advisors LLC6.0%
Polar Capital Holdings Plc4.7%
Driehaus Capital Management LLC4.6%
Jupiter Topco LLC4.3%
T. Rowe Price Associates3.4%
JPMorgan Chase & Co2.7%
Capital International Investors2.4%
T. Rowe Price Investment Management, Inc.2.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)9.65M9.98%$582M-11%
BlackRock, Inc.7.52M7.78%$454M+33%
Avoro Capital Advisors LLC5.78M5.98%$349MNo change
Polar Capital Holdings Plc4.57M4.73%$276M+4%
Driehaus Capital Management LLC4.42M4.57%$267M-2%
Jupiter Topco LLC4.19M4.33%$253M–
T. Rowe Price Associates3.25M3.36%$196M+144%
JPMorgan Chase & Co2.62M2.71%$157M–
Capital International Investors2.36M2.44%$143M-12%
T. Rowe Price Investment Management, Inc.2.17M2.24%$131M+128%
State Street Corp1.97M2.04%$119M+14%
Two Sigma Investments, LP1.64M1.70%$99.2M+171%
Deerfield Management Company, L.P.1.62M1.67%$97.5MNo change
Affinity Asset Advisors, LLC1.59M1.65%$96.3M-5%
Alliancebernstein L.P.1.56M1.62%$90.8M+11%
Westfield Capital Management Co LP1.51M1.56%$91M+8%
Franklin Resources Inc1.44M1.49%$86.8M+12%
Wellington Management Group LLP1.43M1.47%$86M-70%
Citadel Advisors LLC1.40M1.45%$84.6M-47%
Geode Capital Management, LLC1.37M1.42%$82.7M+25%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, XENE insiders reported $1.7M of open-market purchases and $22M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.7M
2 trades, 2 people
Sales, 12 months
$22M
26 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 30, 2026
Filed Oct 1, 2026

Purchases and sales by month

$17.8M$17.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 30, 2026Thomas Patrick KellyCFOPurchase15,000$37.32$560KForm 4
Sep 30, 2026Ian MortimerCEOPurchase30,000$37.38$1.1MForm 4
Aug 28, 2026Christopher John KenneyChief Medical OfficerSale6,368$60.17$383KForm 4
Aug 28, 2026Christopher John KenneyChief Medical OfficerSale700$60.98$42.7KForm 4
Aug 11, 2026Steven GannonDirectorSale10,000$64.06$641KForm 4
Jun 5, 2026Gary PatouDirectorSale1,322$53.14$70.3KForm 4
Jun 5, 2026Gillian CannonDirectorSale1,190$53.14$63.2KForm 4
Mar 13, 2026Christopher John KenneyChief Medical OfficerSale1,410$55.23$77.9KForm 4
Mar 13, 2026Andrea DiFabioChief Legal OfficerSale1,342$55.23$74.1KForm 4
Mar 13, 2026Ian MortimerCEOSale7,308$55.23$404KForm 4
Mar 10, 2026Christopher John KenneyChief Medical OfficerSale2,771$60.11$167KForm 4
Mar 10, 2026Andrea DiFabioChief Legal OfficerSale2,607$60.11$157KForm 4
Mar 10, 2026Ian MortimerCEOSale11,269$60.11$677KForm 4
Mar 9, 2026Ian MortimerCEOSale21,791$58.81$1.3MForm 4
Mar 9, 2026Ian MortimerCEOSale31,694$59.88$1.9MForm 4
Mar 9, 2026Ian MortimerCEOSale21,515$60.49$1.3MForm 4
Mar 9, 2026Ian MortimerCEOSale12,479$59.50$743KForm 4
Mar 9, 2026Ian MortimerCEOSale10,072$60.47$609KForm 4
Mar 9, 2026Ian MortimerCEOSale2,449$61.26$150KForm 4
Mar 9, 2026Ian MortimerCEOSale43,348$59.26$2.6MForm 4
Mar 9, 2026Ian MortimerCEOSale61,652$60.08$3.7MForm 4
Mar 9, 2026Ian MortimerCEOSale65,000$62.06$4MForm 4
Jan 2, 2026Ian MortimerCEOSale37,938$44.40$1.7MForm 4
Jan 2, 2026Ian MortimerCEOSale2,062$44.93$92.6KForm 4
Dec 8, 2025Ian MortimerCEOSale2,010$46.32$93.1KForm 4
Dec 8, 2025Ian MortimerCEOSale8,820$45.59$402KForm 4
Dec 5, 2025Ian MortimerCEOSale14,375$45.03$647KForm 4
Nov 28, 2025Ian MortimerCEOSale97$45.01$4.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ian MortimerPRESIDENT & CEO, Director$1.1M$20.3MSep 30, 2026
Christopher John KenneyChief Medical Officer–$670KAug 28, 2026
Steven GannonDirector–$641KAug 11, 2026
Thomas Patrick KellyChief Financial Officer$560K–Sep 30, 2026
Andrea DiFabioChief Legal Officer–$231KMar 13, 2026
Gary PatouDirector–$70.3KJun 5, 2026
Gillian CannonDirector–$63.2KJun 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

XENE short interest

Moderate short interest. 7.6% of XENE shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 92%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.36M XENE shares were sold short, 7.6% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 6.4 trading days (days to cover).

Shares short, % of all shares

7.60%May 15Oct 308.15%

Days to cover

6.4May 15Oct 3013.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.36M7.60%+0%1.16M6.4
Oct 15, 20267.35M7.59%+22%1.86M4.0
Sep 30, 20266.04M6.24%-6%3.83M1.6
Sep 15, 20266.44M6.66%+2%527,34512.2
Aug 31, 20266.34M6.55%+12%698,2759.1
Aug 14, 20265.67M5.85%+5%618,6359.2
Jul 31, 20265.38M5.57%-15%734,5327.3
Jul 15, 20266.34M6.56%+1%1.78M3.6
Jun 30, 20266.26M6.47%+42%2.11M3.0
Jun 15, 20264.41M4.56%+9%1.38M3.2
May 29, 20264.04M4.18%+6%1.38M2.9
May 15, 20263.83M3.97%-8%947,8464.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Xenon Pharmaceuticals company events

Xenon Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jun 3, 2026LeadershipAs discussed in Item 5.07 below, upon the recommendation of the Board of Directors of Xenon Pharmaceuticals Inc., the shareholders of the Company, at the Company's annual meeting of shareholders held on June 2, 2026, approved the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan, to replace the… Filing
  4. May 7, 2026ResultsReleased financial results. Filing
  5. Apr 13, 2026LeadershipXenon Pharmaceuticals Inc. amended and restated the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement Plan from… Filing
  6. Mar 13, 2026AnnouncementXenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2026 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada. Filing
  7. Mar 12, 2026AgreementThe information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. Filing
  8. Mar 9, 2026AnnouncementShared information with investors. Filing
  9. Feb 27, 2026AnnouncementXenon Pharmaceuticals Inc. filed a prospectus supplement with the Securities and Exchange Commission to register $400 million of common shares, without par value issuable pursuant to the at-the-market equity offering sales agreement, dated August 6, 2020, as amended on March 1, 2022, by and among… Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Dec 1, 2025LeadershipXenon Pharmaceuticals Inc. amended and restated the Company’s 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement Plan from 775,000 shares to 900,000… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Xenon Pharmaceuticals financials

Famous investors that hold XENE

4 of the 50 well-known investors we track reported holding XENE in their latest 13F filing. The largest position is Steve Cohen's, worth $44.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.19M$44.3M0.1%+813%
Ken Griffin · Citadel AdvisorsQ3 2026322,498$12M0.0%-77%
Jim Simons · Renaissance TechnologiesQ3 2026277,200$10.3M0.0%+48%
Paul Tudor Jones · Tudor Investment CorpQ3 202616,483$613K0.0%-97%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named XENE in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Polar Capital Holdings Plc13G5.2%
Nov 16, 2026Polar Capital Holdings Plc13G5.2%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G8.2%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G8.2%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A10.3%
Nov 6, 2026T. Rowe Price Investment Management, Inc.13G/A10.3%
Nov 5, 2026FMR LLC13G/A11.5%
Nov 5, 2026FMR LLC13G/A11.5%

Questions about Xenon Pharmaceuticals Inc. (XENE) stock

Who owns the most XENE stock?

The largest reported owner of Xenon Pharmaceuticals Inc. (XENE) is FMR LLC (Fidelity), with 10.0% of the company. In total, 314 funds and institutions reported holding XENE at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are XENE insiders buying or selling?

In the last 12 months, XENE insiders reported 2 open-market purchases worth $1.7M and 26 sales worth $22M. The latest trade was on Sep 30, 2026. See every trade.

What is the short interest in XENE?

As of Oct 30, 2026, 7.36M XENE shares were sold short, 7.6% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.

Which famous investors hold XENE?

4 of the 50 well-known investors we track reported XENE in their latest 13F filing, including Steve Cohen, Ken Griffin, Jim Simons. The largest position is worth $44.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.